
Amine-PEG-Maleimide (NH2-PEG-MAL) from Advanced BioChemicals (ABC) are high quality linear heterobifunctional PEG derivatives with one amino group and one maleimide group, which can be used as crosslinkers or spacers between two different chemical reagents. Maleimide group can selectively react with thiol groups at pH 5.0-6.5 and amino group can quickly react with carboxyl or activated NHS ester. The HCl salt form provides stability for the solid form of NH2-PEG-MAL.
Advanced BioChemicals (ABC) offer NH2-PEG-MAL with MW 2kDa, MW 3.5 kDa, MW 5kDa, MW 10kDa and MW 20kDa, in 100mg, 500mg, 1g and 5g packing sizes. Different MW of NH2-PEG-MAL products may be available by custom synthesis, please contact us at sales@advancedbiochemicals.com for a free quote.
MW | 2K, 3.5K, 5K, 10K, 20K |
---|---|
Pack Size | 100mg, 500mg, 1g, 5g |
HEP0201-100mg | 2K | 100mg | $150.00 |
HEP0201-500mg | 2K | 500mg | $250.00 |
HEP0201-1g | 2K | 1g | $350.00 |
HEP0201-5g | 2K | 5g | $1,350.00 |
HEP0202-100mg | 3.5K | 100mg | $150.00 |
HEP0202-500mg | 3.5K | 500mg | $250.00 |
HEP0202-1g | 3.5K | 1g | $350.00 |
HEP0202-5g | 3.5K | 5g | $1,350.00 |
HEP0203-100mg | 5K | 100mg | $150.00 |
HEP0203-500mg | 5K | 500mg | $250.00 |
HEP0203-1g | 5K | 1g | $350.00 |
HEP0203-5g | 5K | 5g | $1,350.00 |
HEP0204-100mg | 10K | 100mg | $150.00 |
HEP0204-500mg | 10K | 500mg | $250.00 |
HEP0204-1g | 10K | 1g | $350.00 |
HEP0204-5g | 10K | 5g | $1,350.00 |
HEP0205-100mg | 20K | 100mg | $150.00 |
HEP0205-500mg | 20K | 500mg | $250.00 |
HEP0205-1g | 20K | 1g | $350.00 |
HEP0205-5g | 20K | 5g | $1,350.00 |
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
B、是重要的储能物质,磷脂为构成生物膜的重要成分,固醇为动物细胞膜的构成物质及形成激素等,B错误;
C、蛋白质是细胞代谢的主要结构物质,糖类是细胞代谢的主要能源物质C错误;
D、ATP的结构简式是 A-P~P~P,其中A代表腺苷,腺苷是构成ATP的重要部分,D正确.
故选:D.
http://care.diabetesjournals.org/cgi/content/abstract/31/8/1479
OBJECTIVE—Hyperglycemiaisariskfactorformicrovascularcomplicationsandmayincreasetheriskofcardiovasculardiseaseinpatientswithtype2diabetes.ThisstudytestedtheLDLcholesterol–loweringagentcolesevelamHCl(colesevelam)asapotentialnoveltreatmentforimprovingglycemiccontrolinpatientswithtype2diabetesonsulfonylurea-basedtherapy.
RESEARCHDESIGNANDMETHODS—A26-week,randomized,double-blind,placebo-controlled,parallel-group,multicenterstudywascarriedoutbetweenAugust2004andAugust2006toevaluatetheefficacyandsafetyofcolesevelamforreducingA1Cinadultswithtype2diabeteswhoseglycemiccontrolwasinadequate(A1C7.5–9.5%)withexistingsulfonylureamonotherapyorsulfonylureaincombinationwithadditionaloralanti-diabetesagents.Intotal,461patientswererandomized(230givencolesevelam3.75g/dayand231givenplacebo).Theprimaryefficacymeasurementwasmeanplacebo-correctedchangeinA1Cfrombaselinetoweek26intheintent-to-treatpopulation(lastobservationcarriedforward).
RESULTS—Theleastsquares(LS)meanchangeinA1Cfrombaselinetoweek26was–0.32%inthecolesevelamgroupand+0.23%intheplacebogroup,resultinginatreatmentdifferenceof–0.54%(P<0.001).TheLSmeanpercentchangeinLDLcholesterolfrombaselinetoweek26was–16.1%inthecolesevelamgroupand+0.6%intheplacebogroup,resultinginatreatmentdifferenceof–16.7%(P<0.001).FurThermore,significantreductionsinfastingplasmaglucose,fructosamine,totalcholesterol,non–HDLcholesterol,andapolipoproteinBweredemonstratedinthecolesevelamrelativetoplacebogroupatweek26.
CONCLUSIONS—ColesevelamimprovedglycemiccontrolandreducedLDLcholesterollevelsinpatientswithtype2diabetesreceivingsulfonylurea-basedtherapy.
这个“类”是什么意思?
为了帮助临床医师客观地了解NSAIDs,避开制药公司的导向以便更好地指导临床实践,本报请广州中山大学附属第一医院风湿免疫内科杨岫岩教授向读者介绍NSAIDs临床应用的一些问题。
NSAIDs的发展
从乙酰水杨酸(阿司匹林)应用至临床到现在,已经超过100个年头。1948年第一个非水杨酸类的NSAIDs保泰松问世后,抗炎镇痛药的种类迅速增加,如吲哚美辛、双氯芬酸、布洛芬、萘普生等,使NSAIDs“家族”迅速壮大。作为其“元老”的保泰松,虽然具有很强的抗炎镇痛作用,但潜在的严重副作用(再生障碍性贫血等)使其被淘汰。
1971年,环氧化酶(COX)理论解释了NSAIDs的作用机制。NSAIDs通过抑制COX,阻止花生四烯酸转变为前列腺素,后者既是炎症介质,又有生理功能。因此NSAIDs在抗炎镇痛的同时可引起胃肠道反应。20年后,研究者发现,COX存在不同的异构体,从而提出了COX异构体理论。认为COX存在两个异构体,一个是构建型的,称COX-1,以维持生理平衡为主;另一个是诱导型的称COX-2,主要参与炎症性前列腺素合成。
1994年,氟舒胺成为第一个被报道在实验室证实具有选择性COX-2抑制作用的NSAIDs,但在1996年III期临床试验总结时发现,该药具有肝毒性而未能获准上市。1995年Lancet上首先称萘丁美酮、美洛昔康、尼美舒利等为“选择性COX-2抑制剂”,虽然同年该期刊刊出几篇读者来信,对此提法提出争议,但是后来人们仍普遍接受这种提法。1999年,针对COX异构体理论研制的昔布类药物(塞来昔布和罗非昔布)上市,被称为“特异性COX-2抑制剂”。
虽然COX异构体理论尚需完善,但它的确是新型NSAIDs研制的一个突破口。除已经问世的昔布类药物外,新的昔布类Etoricoxib、parecoxib、valdecoxib也将投入临床。新研制的COX-2抑制剂不只限于昔布类,磺酰苯胺类也是研制新型COX-2抑制剂的方向,如氟舒胺、NS-398、HN-56249等。另外,针对COX和脂氧化酶(5-lipoxygenase

